1. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib
- Author
-
Wei Guo, Yun-Ping Zhao, Li Wang, Bin Guo, Kun Li, Shuhui Liang, Xiaoqing Fan, Ru-Wen Wang, Shukui Qin, and Yao-Guang Jiang
- Subjects
Esophageal Neoplasms ,Dasatinib ,Mice, Nude ,Antineoplastic Agents ,Apoptosis ,Cell Cycle Proteins ,Docetaxel ,Cell Line ,Mice ,Cell Line, Tumor ,hemic and lymphatic diseases ,Carcinoma ,Animals ,Humans ,Medicine ,Src family kinase ,Phosphorylation ,Kinase activity ,Proto-Oncogene Proteins c-abl ,Protein Kinase Inhibitors ,Cell Proliferation ,Mice, Inbred BALB C ,ABL ,Cell growth ,business.industry ,Calcium-Binding Proteins ,Cell Cycle ,Drug Synergism ,General Medicine ,medicine.disease ,Xenograft Model Antitumor Assays ,Up-Regulation ,Repressor Proteins ,Thiazoles ,Pyrimidines ,src-Family Kinases ,Mad2 Proteins ,Carcinoma, Squamous Cell ,Cancer research ,Female ,Taxoids ,business ,Tyrosine kinase ,Proto-oncogene tyrosine-protein kinase Src ,medicine.drug - Abstract
Aberrant expression and/or activity of the non-receptor protein tyrosine kinase SFK (Src family kinase) members are commonly observed in progressive stages of human tumours. The aim of the present study was to investigate whether Src is a potential drug target for treating oesophageal squamous cell carcinoma. Compared with the human immortalized oesophageal epithelial cell line SHEE, oesophageal squamous cell carcinoma cells have increased tyrosine phosphorylation activities. We have explored the therapeutic potential of dasatinib, a small-molecule inhibitor that targets multiple cytosolic and membrane-bound tyrosine kinases, for the treatment of oesophageal squamous cell carcinoma. We examined that the effects of dasatinib on proliferation, invasion, apoptosis, spindle checkpoint, cell-cycle arrest and kinase activity in vitro using three human oesophageal carcinoma cell lines KYSE30, KYSE180 and EC109. In nude mouse models, dasatinib treatment effectively inhibited the expression of activated Src, resulting in the inhibition of tumour growth. Multiple drug effect isobologram analysis was used to study interactions with the chemotherapeutic drug docetaxel. As expected, the three oesophageal carcinoma cell lines were highly sensitive to dasatinib, but SHEE cells were not sensitive to this drug. Concentration-dependent anti-proliferative effects of dasatinib were observed in the three oesophageal carcinoma cell lines. Dasatinib significantly inhibited oesophageal carcinoma cell invasion and up-regulation of MAD2 (mitotic arrest-deficient 2), as well as inducing cell apoptosis and cell-cycle arrest. Additive and synergistic interactions were observed for the combination of dasatinib and docetaxel. Therefore it was concluded that dasatinib blocks the G1/S transition and inhibits cell growth. These results provided a clear biological rationale to test dasatinib as a single agent or in combination with chemotherapy in oesophageal squamous cell carcinoma. Moreover, we have shown in vitro and in vivo that dasatinib might have therapeutic benefit for patients with oesophageal squamous cell carcinoma who are not eligible for surgery.
- Published
- 2011